Crosspoint Capital Strategies’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Crosspoint Capital Strategies’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-104,573	Closed	-$1.86M	–	66
2018 Q3	$1.86M	Sell	104,573 -3,047	-3%	-$52.3K	3.04%	10
2018 Q2	$1.49M	Buy	+107,620	New	+$1.28M	2.84%	14
2016 Q1	–	Sell	-210	Closed	-$1K	–	933
2015 Q4	$1K	Buy	+210	New	+$967	﹤0.01%	975

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Crosspoint Capital Strategies's ECYT Position: Q4 2018 in Review

Crosspoint Capital Strategies sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 104,573 shares — an estimated $1.86M sold.

Crosspoint Capital Strategies first reported a position in ECYT in Q4 2015 and held it in 3 quarters. The position peaked at $1.86M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Crosspoint Capital Strategies reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Crosspoint Capital Strategies sold 104,573 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $1.86M.
Crosspoint Capital Strategies first reported a position in Endocyte, Inc. Common Stock in Q4 2015 and held it in 3 quarters.
Crosspoint Capital Strategies's Endocyte, Inc. Common Stock position peaked at $1.86M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2018, filed 13 Feb 2019.